Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. (June 2016)

• Record Type: Journal Article
• Authors: Schlenkhoff, Carl Diedrich; Gaertner, Florian; Essler, Markus; Schmidt, Matthias; Ahmadzadehfar, Hojjat
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 6(2016)
• Publication Date: 2016-06
• Subjects: 177Lu-PSMA therapy -- castrate resistant -- prostate cancer -- 68Ga-PSMA-PET/CT -- bone marrow depression -- anemia; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001195
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during 223 Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.